Pricing Reimbursment and Market Acces NewsletterPricing Reimbursment and Market Acces Issue #22ViiV Healthcare submits regulatory applications for the first HIV maintenance regimen comprising only two medicinesJun 4, 2017Jun 4, 2017
Pricing Reimbursment and Market Acces NewsletterPricing Reimbursment and Market Acces Newsletter #21NICE terminates appraisal of afatinib dimaleateMay 28, 2017May 28, 2017
Pricing Reimbursment and Market Acces NewsletterPricing Reimbursment and Market Acces Newsletter #20FDA approves Merck’s Keytruda (pembrolizumab) for certain patients with locally advanced or metastatic urothelial carcinoma, a type of…May 20, 2017May 20, 2017
Pricing Reimbursment and Market Acces NewsletterPricing Reimbursment and Market Acces Issue #19Institute for Clinical and Economic Review releases revised evidence report on dupilumab and crisaborole for treatment of atopic dermatitisMay 13, 2017May 13, 2017
Pricing Reimbursment and Market Acces NewsletterPricing Reimbursment and Market Acces Newsletter #18Roche receives FDA approval for complementary PD-L1 (SP263) biomarker test in urothelial carcinomaMay 6, 2017May 6, 2017
Pricing Reimbursment and Market Acces NewsletterPricing Reimbursment and Market Acces Newsletter #17Marketing authorisation for Glybera to expire on 25 October 2017Apr 29, 2017Apr 29, 2017
Pricing Reimbursment and Market Acces NewsletterPricing Reimbursment and Market Acces Newsletter #16FDA approves Samsung Bioepis’ copy of J&J’s RemicadeApr 22, 2017Apr 22, 2017
